Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHFINDER: ipatasertib combinations in taxane-pretreated advanced triple-negative breast cancer
2018-004648-44Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipatasertib in triple-negative breast cancer (TNBC) (3 arms), sponsored by MEDSIR. Primary endpoint: Incidence of adverse events. Started Apr 2020; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2018-004648-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004648-44.